Although our studies primarily focused on murine melanoma and did not address whether clock function is perturbed in human melanomas to induce mesenchymal transition and therapy resistance, a recent study about human prostate cancer demonstrated that human BMAL1 is elevated and necessary for enzulutamide resistance30. The gene discussed is BMAL1; the disease is melanoma.